PAM, the Evil "Twin" of PsA, May Resist DMARDs
Psoriatic arthritis mutilans seems to progress despite DMARD treatment and many patients have axial disease.
Patients Get a Voice in PsA Guidelines and Research
Outcomes in psoriatic arthritis should improve, representatives of the research body GRAPPA assert, now that patients are gaining a role in creating symptom measures and definitions.
Coming Soon: North American Guidelines for AS and AxSpA
Do European guidelines for axial spondylitis adequately address patient needs on the other side of the Atlantic?
Creating a Molecular Crystal Ball for PsA
Progress report from GRAPPA 2014.on the PsA BioDam (biomarkers of damage in psoriatic arthritis) study.
Despite New Drugs, PsA Treatment Options Still Fall Short
A third of psoriatic arthritis patients do not respond well to TNF-blockers and DMARDs. So there’s an urgent quest for new targeted drugs
Making Psoriatic Arthritis Harder to Miss
At its 2014 annual meeting, GRAPPA continues development of criteria to help non-rheumatologists spot psoriatic arthritis.
By clicking Accept, you agree to become a member of the UBM Medica Community.